How to choose eltrombopag, heltrombopag or avatropopag?

There are several factors to consider when choosing between eltrombopag, heltrombopag, or avatropopag.

Eltrombopag is a thrombopoietin receptor agonist that stimulates the proliferation and differentiation of the bone marrow megakaryocytic system by interacting with the transmembrane domain of the TPO receptor, thereby promoting the production and release of platelets. It is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura and in patients who have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy. However, eltrombopag has a moiety that has the potential to produce hepatotoxic effects and needs to be taken at intervals between food and other medications.

Eltrombopag is a thrombopoietin receptor agonist similar to eltrombopag. Its pharmacokinetic properties are not fully understood, but it is known to have some hepatotoxicity. The method of taking Hetrombopag has not yet been fully clarified, and there may be certain food or drug interactions. Therefore, when choosing heltrombopag, one needs to pay close attention to its potential risk of hepatotoxicity.

Avatrombopag is another thrombopoietin receptor agonist that is not metabolized by UGT and has no hepatotoxicity. This makes avatrombopag the drug of choice for patients with hepatic impairment. In addition, avatrombopag can be used in children and adolescent patients. Its administration is relatively simple and can be taken with food. However, there are relatively few safety data for avatrombopag in pregnant and lactating women and caution should be used.

For patients with normal liver function, eltrombopag and heltrombopag may be appropriate options. However, in patients with hepatic impairment, avatrombopag has an advantage due to its lack of hepatotoxicity.

The method of taking avatrombopag is relatively simple and can be taken with food, which is more convenient for patients who require long-term medication. For eltrombopag and eltrombopag, interactions with food and other medications need to be considered.

Eltrombopag may increase the risk of bleeding and may cause hepatotoxicity. Hetrombopag also carries some risk of hepatotoxicity. In contrast, avatrombopag has relatively few side effects, is not metabolized by UGT, and has no hepatotoxicity.

Avatrombopag is a better option for children and adolescents because of its proven safety and effectiveness. However, there are relatively few safety data for all three drugs in pregnant and lactating women and they need to be used with caution.

When selecting eltrombopag, heltrombopag, or avatropopag, the patient's specific circumstances and needs should be considered. For patients with normal liver function, eltrombopag and heltrombopag may be suitable choices; while for patients with hepatic impairment, avitrombopag has an advantage due to its lack of hepatotoxicity. In addition, factors such as convenience of medication and risk of side effects also need to be considered.

When choosing drugs, it is recommended to consult a professional doctor and formulate a personalized treatment plan based on the patient's specific situation. At the same time, patients should pay close attention to their physical condition when using these drugs and promptly report any abnormalities to their doctors so that the treatment plan can be adjusted in a timely manner to ensure the safety and effectiveness of the medication.